MARKET

APTX

APTX

Aptinyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.250
-0.110
-3.27%
After Hours: 3.200 -0.05 -1.54% 19:55 06/17 EDT
OPEN
3.333
PREV CLOSE
3.360
HIGH
3.402
LOW
3.180
VOLUME
829.40K
TURNOVER
--
52 WEEK HIGH
6.47
52 WEEK LOW
2.300
MARKET CAP
221.56M
P/E (TTM)
-3.5112
1D
5D
1M
3M
1Y
5Y
Aptinyx to Participate in Upcoming Investor Conferences
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the Company will be participating in two upcoming investor conferences:
Business Wire · 14h ago
Oracle, Roblox among premarket losers' pack
Inhibikase Therapeutics IKT -24% after prices stock offering at $3Blue Apron Holdings APRN -19% after announcing share offering.Alfi (ALF) -14%.Clearside Biomedical (CLSD) -10%.TAL Education (TAL) -10%.TDH Holdings (PETZ) -10%.Unique Fabricating (UFAB) -9%...
Seekingalpha · 1d ago
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15)
Benzinga · 1d ago
Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
Benzinga · 1d ago
CATB, XELB, CLSD and DTEA among after-hours movers
Gainers: [[CATB]] +47.1%. [[XELB]] +16.1%. [[TOUR]] +8.3%. [[PDD]] +6.4%. [[SGMO]] +5.1%.Losers: [[APTX]] -9.5%. [[CLSD]] -8.3%. [[DTEA]] -8.2%. [[ETTX]] -5.1%. [[GBS]] -4.6%.
Seekingalpha · 2d ago
BRIEF-Aptinyx Provides Update On Nyx-783 Development Program For The Treatment Of Post-Traumatic Stress Disorder
reuters.com · 2d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 2d ago
Aptinyx updates on mid-stage clinical program for PTSD therapy
Devonyu/iStock via Getty Images Aptinyx (APTX) says that after a Type C meeting with the FDA held recently it has finalized the design of its Phase 2b program for NYX-783 in patients
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APTX. Analyze the recent business situations of Aptinyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APTX stock price target is 10.29 with a high estimate of 12.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 101
Institutional Holdings: 40.99M
% Owned: 60.12%
Shares Outstanding: 68.17M
TypeInstitutionsShares
Increased
26
5.06M
New
9
136.47K
Decreased
15
1.22M
Sold Out
13
838.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.12%
Pharmaceuticals & Medical Research
+0.27%
Key Executives
Chairman/Independent Director
Patrick Enright
President/Chief Operating Officer
Andrew Kidd
Chief Executive Officer/Director
Norbert Riedel
Chief Financial Officer
Ashish Khanna
Independent Director
Henry Gosebruch
Independent Director
Elisha Gould
Independent Director
Robert Hombach
Independent Director
Adam Koppel
Independent Director
Joan Miller
Independent Director
Rachel Sherman
No Data
About APTX
Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.

Webull offers kinds of Aptinyx Inc stock information, including NASDAQ:APTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APTX stock methods without spending real money on the virtual paper trading platform.